TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12460699

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 15 mg/day)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Fosinopril (10 to 30 mg/day)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Amlodipine plus Fosinopril (5/10 to 15/30 mg/day)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 309
Study: 10554808

Group type: EXPERIMENTAL
Intervention: Granulocyte‐CSF (G‐CSF) + Erythropoietin (EPO)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with ringed sideroblastic anaemia (RARS)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with 5q -
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with high transfusion need
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with refractory anaemia with an excess of blasts (RAEB)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Patients with RARS and thrombocytosis who normalized their platelet counts
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 8533910

Group type: EXPERIMENTAL
Intervention: 40 mg oral famotidine 3 h before induction of anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1758322

Group type: EXPERIMENTAL
Intervention: Group teaching in problem-based interviewing with video and audiotape feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Watching their own consultations in a group feedback setting
Number of subjects: 0

Group type: COMPARATOR
Intervention: Video feedback of tutorial sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Discussion about how to teach
Number of subjects: 0

Group type: COMPARATOR
Intervention: No further teaching
Number of subjects: 0
Study: 7036291

Group type: EXPERIMENTAL
Intervention: Immunostimulation (BCG or levamisole) with chemotherapy dimethyl ‐ triazeno ‐ imidazole ‐ carboxamide (DTIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New agents being screened for stage III melanoma
Number of subjects: 0
Study: 31780869

Group type: EXPERIMENTAL
Intervention: CSF MMP-8 concentration above the median
Number of subjects: 245
Study: 30566485

Group type: EXPERIMENTAL
Intervention: Condition 2 - recommended (theory-based) information correction
Number of subjects: 243

Group type: COMPARATOR
Intervention: Condition 1 - common information correction
Number of subjects: 243
Study: 26363307

Group type: EXPERIMENTAL
Intervention: Combined peer and parent intervention (n=342)
Number of subjects: 680

Group type: COMPARATOR
Intervention: Assessment-only control (n=338)
Number of subjects: 680
Study: 25083802

Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LG‐CC)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 304
Study: 22116797

Group type: EXPERIMENTAL
Intervention: Modern draisine
Number of subjects: 21

Group type: COMPARATOR
Intervention: Rollator
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both walking aids
Number of subjects: 21
Study: 21055597

Group type: EXPERIMENTAL
Intervention: Bone-anchored maxillary protraction (BAMP)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (untreated Class III subjects)
Number of subjects: 21
Study: 17682590

Group type: EXPERIMENTAL
Intervention: Educational games
Number of subjects: 34

Group type: COMPARATOR
Intervention: Standard education techniques (Control)
Number of subjects: 34
Study: 17557470

Group type: EXPERIMENTAL
Intervention: Zaleplon 10 mg
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Zolpidem 10 mg
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 12594140

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine + clonidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 45

Group type: COMPARATOR
Intervention: i.v. morphine (control group)
Number of subjects: 45
Study: 11012468

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Omeprazole 20 mg
Number of subjects: 1960
Study: 8816618

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No GnRH agonist (control group A)
Number of subjects: 100
Study: 1609047

Group type: EXPERIMENTAL
Intervention: Haloperidol (1-3 mg daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Thioridazine (25-75 mg daily)
Number of subjects: 68
Study: 6388341

Group type: EXPERIMENTAL
Intervention: Bonded brackets and eyelets
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (bonded contralaterally and at random)
Number of subjects: 2
Study: 29998861

Group type: EXPERIMENTAL
Intervention: Er:YAG laser ablation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Motorized dermabrasion
Number of subjects: 32
Study: 30251639

Group type: EXPERIMENTAL
Intervention: Initial resuscitation with FiO2 0.21
Number of subjects: 240

Group type: COMPARATOR
Intervention: Initial resuscitation with FiO2 1.0
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: FiO2 0.21
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 5-minute blood oxygen saturation (SpO2) <80%
Number of subjects: 240
Study: 27068684

Group type: EXPERIMENTAL
Intervention: Healthy Start‐Départ Santé intervention
Number of subjects: 61
Study: 23348662

Group type: EXPERIMENTAL
Intervention: Light-intensity exercise intervention using virtual-reality (Nintendo Wii Fit Plus)
Number of subjects: 7
Study: 22553044

Group type: EXPERIMENTAL
Intervention: FAST (Fast Alcohol Screening Test)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: M-SASQ (modified version of the Single Alcohol Screening Question)
Number of subjects: 205

Group type: COMPARATOR
Intervention: AUDIT (Alcohol Use Disorders Identification Test)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Probation setting
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 205

Group type: COMPARATOR
Intervention: Violent offences
Number of subjects: 205

Group type: COMPARATOR
Intervention: Property offences
Number of subjects: 205
Study: 21055649

Group type: EXPERIMENTAL
Intervention: HFMS (Alere DayLink HF Monitoring System)
Number of subjects: 315

Group type: COMPARATOR
Intervention: SC (Standard Care)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: HFMS
Number of subjects: 315

Group type: COMPARATOR
Intervention: SC
Number of subjects: 315
Study: 18043058

Group type: EXPERIMENTAL
Intervention: P6 acupuncture group (n = 110)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group (n = 110)
Number of subjects: 220
Study: 16102903

Group type: EXPERIMENTAL
Intervention: LRRK 2 G 2019 S mutation screening in Parkinson's disease patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: LRRK 2 G 2019 S mutation screening in other neurodegenerative diseases (Alzheimer's, Progressive Supranuclear Palsy, Multiple System Atrophy, frontotemporal dementia)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neurologically normal controls
Number of subjects: 0
Study: 12239432

Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type I
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type II
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type III
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene plasma levels in skin type IV
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene content in oral mucosa epithelium (OMC) in skin type I
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene content in oral mucosa epithelium (OMC) in skin type IV
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene content in OMC in skin type I
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Beta-carotene content in OMC in skin type IV
Number of subjects: 174

Group type: COMPARATOR
Intervention: Comparison of beta-carotene levels in smokers vs non-smokers
Number of subjects: 174

Group type: COMPARATOR
Intervention: Comparison of beta-carotene levels in non-melanoma and melanoma skin cancer patients
Number of subjects: 174
Study: 10221882

Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 85

Group type: COMPARATOR
Intervention: Nystatin
Number of subjects: 85
Study: 7593706

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 139

Group type: COMPARATOR
Intervention: haloperidol
Number of subjects: 139

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 139
Study: 2390431

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ICS 205-930 (10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6291763

Group type: EXPERIMENTAL
Intervention: CAM combination chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single‐agent sequential chemotherapy (cyclophosphamide, doxorubicin, and methotrexate)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: CAM combination chemotherapy
Number of subjects: 104

Group type: COMPARATOR
Intervention: Single‐agent sequential chemotherapy
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Overall survival for CAM
Number of subjects: 104

Group type: COMPARATOR
Intervention: Overall survival for single-agent sequential chemotherapy
Number of subjects: 104
Study: 31204078

Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 27
Study: 28816924

Group type: EXPERIMENTAL
Intervention: DRSP/EE (drospirenone and ethinyl estradiol)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 26799573

Group type: EXPERIMENTAL
Intervention: Magnetic resonance therapy (MRT) - 10 sessions of one hour daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo MRT
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Magnetic resonance therapy (MRT)
Number of subjects: 97
Study: 25347024

Group type: EXPERIMENTAL
Intervention: PBS skills training intervention
Number of subjects: 226

Group type: COMPARATOR
Intervention: Study skills control condition
Number of subjects: 226
Study: 23093256

Group type: EXPERIMENTAL
Intervention: 90 mg progesterone vaginal gel
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 19789415

Group type: EXPERIMENTAL
Intervention: Preterax (2 mg perindopril/0.625 mg indapamide)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cilazapril (2.5 mg)
Number of subjects: 30
Study: 17257820

Group type: EXPERIMENTAL
Intervention: NIPSV (noninvasive pressure support ventilation) administered pre‐ and postoperatively for 7 days at home before surgery and 3 days postoperatively
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: NIPSV
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no NIPSV)
Number of subjects: 32
Study: 14982787

Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin (single doses starting at 140 mg, escalating to 1120 mg; multiple doses with a 300 mg loading dose followed by six daily 30 mg maintenance doses)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Intravenous dalbavancin (various doses)
Number of subjects: 52
Study: 11744606

Group type: EXPERIMENTAL
Intervention: Oseltamivir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Probenecid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 0
Study: 9864778

Group type: EXPERIMENTAL
Intervention: Short-term corticosteroid therapy (up to 21 days)
Number of subjects: 0
Study: 7990700

Group type: EXPERIMENTAL
Intervention: Hypocaloric high-protein diet (HP diet, 10 subjects)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Hypocaloric high-carbohydrate diet (HC diet, 15 subjects)
Number of subjects: 25
Study: 2646350

Group type: EXPERIMENTAL
Intervention: Nicergoline, 60 mg daily
Number of subjects: 315

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study: 31012562

Group type: EXPERIMENTAL
Intervention: Topical test product (peptide combination)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bland emollient (control)
Number of subjects: 11
Study: 28679486

Group type: EXPERIMENTAL
Intervention: Leisure time exercise of moderate intensity (MOD, ∼50% VO2peak)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Active commuting (BIKE)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Habitual lifestyle (Control, CON)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Leisure time exercise of vigorous intensity (VIG, ∼70% VO2peak)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Fibrinogen, von Willebrand factor (vWF), tissue-type plasminogen activator (t-PA), plasminogen activator inhibitor type 1 (PAI-1)
Number of subjects: 130
Study: 25727857

Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg) administered weekly over 3 years
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolastin-C (120 mg/kg) administered weekly over 3 years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolastin-C (60 mg/kg) and Prolastin-C (120 mg/kg)
Number of subjects: 0
Study: 23898805

Group type: EXPERIMENTAL
Intervention: Integrated Treatment (IT) (N=30)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU) (N=20)
Number of subjects: 50
Study: 22141750

Group type: EXPERIMENTAL
Intervention: SCP care
Number of subjects: 0

Group type: COMPARATOR
Intervention: usual care
Number of subjects: 0
Study: 19484786

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (4 mg intravenously on Day 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no infusion during ADT)
Number of subjects: 40
Study: 16967399

Group type: EXPERIMENTAL
Intervention: Intermittent nasogastric feeding
Number of subjects: 107

Group type: COMPARATOR
Intervention: Continuous feeding
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: High dose of dopamine
Number of subjects: 107
Study: 15208226

Group type: EXPERIMENTAL
Intervention: Telemedicine consultation
Number of subjects: 600

Group type: COMPARATOR
Intervention: On-site specialist consultation
Number of subjects: 600

Group type: COMPARATOR
Intervention: On-site general practitioner consultation
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: All consultation modalities
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Telemedicine
Number of subjects: 600
Study: 15126176

Group type: EXPERIMENTAL
Intervention: Submacular surgery
Number of subjects: 120

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 120
Study: 10410299

Group type: EXPERIMENTAL
Intervention: DASH diet
Number of subjects: 459

Group type: EXPERIMENTAL
Intervention: Fruits and vegetables diet
Number of subjects: 459

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 459
Study: 8712061

Group type: EXPERIMENTAL
Intervention: PTSD + SUD group
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol-dependent group
Number of subjects: 28
Study: 2193424

Group type: EXPERIMENTAL
Intervention: Protein-free haemodialysate (Actovegin)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 631013

Group type: EXPERIMENTAL
Intervention: Methadone test dose pupillography
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 31533751

Group type: EXPERIMENTAL
Intervention: wIRA treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: no-wIRA treatment (control group)
Number of subjects: 120
Study: 28078599

Group type: EXPERIMENTAL
Intervention: Besifloxacin ophthalmic suspension 0.6%
Number of subjects: 33

Group type: COMPARATOR
Intervention: Gatifloxacin ophthalmic solution 0.3%
Number of subjects: 33
Study: 26270287

Group type: EXPERIMENTAL
Intervention: Community health worker (CHW) home visits
Number of subjects: 373

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 373
Study: 25043278

Group type: EXPERIMENTAL
Intervention: Low-dose sIPV
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Low-dose adjuvanted sIPV
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional IPV (wIPV)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 20
Study: 23159252

Group type: EXPERIMENTAL
Intervention: Decision aid plus personalized risk assessment
Number of subjects: 825

Group type: EXPERIMENTAL
Intervention: Decision aid alone
Number of subjects: 825

Group type: COMPARATOR
Intervention: Control
Number of subjects: 825
Study: 19753300

Group type: EXPERIMENTAL
Intervention: Nebulized rIFN‐gamma1b
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: rIFN‐gamma1b (both nebulized and subcutaneous)
Number of subjects: 89

Group type: COMPARATOR
Intervention: DOTS
Number of subjects: 89

Group type: COMPARATOR
Intervention: Subcutaneous rIFN‐gamma1b
Number of subjects: 89
Study: 17319412

Group type: EXPERIMENTAL
Intervention: Direct laryngoscopy (group-I)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Intubating Laryngeal Mask Airway (group-II)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 15240088

Group type: EXPERIMENTAL
Intervention: Mutual support group (12 sessions over 3 months)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Usual outpatient care only
Number of subjects: 48
Study: 11163560

Group type: EXPERIMENTAL
Intervention: Carmeda Bioactive Surface
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Baxter Duraflo II
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Heparin coating (general)
Number of subjects: 300
Study: 9680884

Group type: EXPERIMENTAL
Intervention: Composite or laminate (sandwich) composite sealant restorations
Number of subjects: 278
Study: 8006914

Group type: EXPERIMENTAL
Intervention: Combination therapy of quinapril and hydrochlorothiazide (HCTZ)
Number of subjects: 460

Group type: COMPARATOR
Intervention: Quinapril monotherapy
Number of subjects: 460

Group type: COMPARATOR
Intervention: HCTZ monotherapy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Quinapril and HCTZ combination therapy
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Quinapril (40 mg) with HCTZ
Number of subjects: 460
Study: 2630288

Group type: EXPERIMENTAL
Intervention: Non-gamma 2 amalgam fillings (30 subjects)
Number of subjects: 45

Group type: COMPARATOR
Intervention: New fillings (15 subjects)
Number of subjects: 45
Study: 31427788

Group type: EXPERIMENTAL
Intervention: Artificial intelligence and game elements decision support approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28684643

Group type: EXPERIMENTAL
Intervention: IVIG plus clarithromycin
Number of subjects: 81

Group type: COMPARATOR
Intervention: IVIG
Number of subjects: 81
Study: 26488734

Group type: EXPERIMENTAL
Intervention: Silver dressings (SD)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Regular dressings (RD)
Number of subjects: 55
Study: 23978167

Group type: EXPERIMENTAL
Intervention: Negative social preference scores based on teacher ratings
Number of subjects: 188
Study: 21484950

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 0
Study: 19516176

Group type: COMPARATOR
Intervention: 100 mg tea flavonoids/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: 200 mg tea flavonoids/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: 400 mg tea flavonoids/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: 800 mg tea flavonoids/day
Number of subjects: 19

Group type: COMPARATOR
Intervention: black tea intake
Number of subjects: 19
Study: 17369570

Group type: EXPERIMENTAL
Intervention: Decision aids
Number of subjects: 0
Study: 15300275

Group type: EXPERIMENTAL
Intervention: Educational intervention carried out in Mushin LGA for four weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control LGA (Ikeja) with no intervention.
Number of subjects: 0
Study: 11479470

Group type: EXPERIMENTAL
Intervention: Stenting with >=1 heparin-coated stent
Number of subjects: 410

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Duration of occlusion <= 6 weeks
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Duration of occlusion > 6 weeks
Number of subjects: 410
Study: 9756247

Group type: EXPERIMENTAL
Intervention: Low-energy density (LED) diet (357 kJ/100 g)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High-energy density (HED) diet (629 kJ/100 g)
Number of subjects: 6
Study: 7923965

Group type: EXPERIMENTAL
Intervention: Captopril pretreatment in normal subjects (group II)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Arginine infusion without captopril (group I)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Arginine infusion in IgA nephropathy patients (group III)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Arginine infusion in normals without captopril (group I)
Number of subjects: 26
Study: 3207855

Group type: EXPERIMENTAL
Intervention: Ergoloid mesylates (3-9 mg) administered via oral swallow and sublingual tablets, solution, under fasted and with meal conditions.
Number of subjects: 0
Study: 31954563

Group type: EXPERIMENTAL
Intervention: High milk replacer (HI) at 1.498 kg of MR/d
Number of subjects: 48

Group type: COMPARATOR
Intervention: Low milk replacer (LO) at 0.749 kg of MR/d
Number of subjects: 48
Study: 31628121

Group type: EXPERIMENTAL
Intervention: Broccoli sprout extract (24 mg of activated sulforaphane, twice daily until delivery)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo (identical to broccoli sprout extract)
Number of subjects: 180
Study: 27935788

Group type: EXPERIMENTAL
Intervention: Endowment condition
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Thoughts structuring instructions
Number of subjects: 102
Study: 25973838

Group type: EXPERIMENTAL
Intervention: Clipping alone (group A)
Number of subjects: 148

Group type: COMPARATOR
Intervention: Clipping plus epinephrine-saline injection (group B)
Number of subjects: 148
Study: 23086020

Group type: EXPERIMENTAL
Intervention: Guanfacine (1 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 22094838

Group type: EXPERIMENTAL
Intervention: Fortified juice drink
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-fortified juice
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 17603709

Group type: EXPERIMENTAL
Intervention: Abbott Propofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pofol
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Propofol 1% Fresenius
Number of subjects: 90